Psoriatic disease is a chronic immune-mediated disease fueled by persistent local and systemic inflammation. Extending beyond the skin, psoriatic inflammation affects multiple body systems and is associated with many comorbid conditions. The manifestations of psoriatic disease include plaque psoriasis, cardiovascular disease (CVD), and bone and joint destruction, to name a few. Psoriasis shares overlapping pathogenic inflammatory pathways with CVD, fueled by vascular and systemic inflammation. The unveiling of multifaceted components of psoriatic disease and its inflammatory pathogenesis has significantly benefited psoriatic patients. The development of monoclonal antibody therapies targeting specific disease-driving proinflammatory cytokines has led to a more comprehensive approach to treating psoriatic patients. Since we now understand the inflammatory link between psoriatic disease and CVD, researchers have sought to identify the positive impact of biologic therapies specifically on CVD in psoriasis patients. However, the precise effect of these biologics on CVD is unclear, although data continues to be collected and analyzed. This review article will attempt to synthesize the acquired information to date.
Craven S. Cardiovascular Comorbidity in Psoriasis and Treatment Options. Lynchburg Journal of Medical Science. 2022; 4(4).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.